Arch Therapeutics, Inc.
Form 424B3
November 18, 2014

Filed Pursuant to Rule 424(b)(3)

Registration No. 333-194745

PROSPECTUS SUPPLEMENT NO. 6 DATED NOVEMBER 18, 2014

TO

PROSPECTUS DATED JULY 2, 2014

(AS SUPPLEMENTED)

ARCH THERAPEUTICS, INC.

PROSPECTUS

Up to 45,600,000 Shares of Common Stock

This Prospectus Supplement No. 6 supplements the prospectus of Arch Therapeutics, Inc. ("the "Company", "we", "us", or "our") dated July 2, 2014 (as supplemented to date, the "Prospectus") with the following attached document which we filed with the Securities and Exchange Commission on November 18, 2014:

A. Our Current Report on Form 8-K filed with the Securities and Exchange Commission on November 18, 2014

This Prospectus Supplement No. 6 should be read in conjunction with the Prospectus, which is required to be delivered with this Prospectus Supplement. This prospectus supplement updates, amends and supplements the information included in the Prospectus. If there is any inconsistency between the information in the Prospectus and this prospectus supplement, you should rely on the information in this prospectus supplement.

This prospectus supplement is not complete without, and may not be delivered or utilized except in connection with, the Prospectus, including any amendments or supplements to it.

Investing in our common stock involves a high degree of risk. Before making any investment in our common stock, you should carefully consider the risk factors for our common stock, which are described in the Prospectus, as amended or supplemented.

You should rely only on the information contained in the Prospectus, as supplemented or amended by this Prospectus Supplement No. 6 and any other prospectus supplement or amendment thereto. We have not authorized anyone to provide you with different information.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.

The date of this Prospectus Supplement No. 6 is November 18, 2014

INDEX TO FILINGS

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): **November 18, 2014**

ARCH THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Nevada	**000-54986**	**46-0524102**
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

20 William Street, Suite 270	
Wellesley, Massachusetts	**02481**
(Address of principal executive offices)	(Zip Code)

Registrant's telephone number, including area code: **(617) 431-2313**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01 Other Events.

On November 18, 2014, Arch Therapeutics, Inc. (the "Company") issued a press release announcing the results of a preclinical study of its AC5 Surgical Hemostatic Device™ in patients treated with the blood thinner Brilinta. The text of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.

Item 9.01 Financial Statements and Exhibit

(d) Exhibits

Exhibit	Description
99.1	Press Release issued by Arch Therapeutics, Inc. on November 18, 2014

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ARCH THERAPEUTICS, INC.

Dated: November 18, 2014 By:/s/ Terrence W. Norchi, M.D.
Name: Terrence W. Norchi, M.D.
Title: President, Chief Executive Officer

EXHIBIT INDEX

Exhibit	Description
99.1	Press Release issued by Arch Therapeutics, Inc. on November 18, 2014

Exhibit 99.1

Arch Therapeutics Reports Positive Preclinical Data from Study of AC5

Surgical Hemostatic Device™ in Animals Treated with Brilinta®
(ticagrelor)

AC5™ Quickly Stopped Bleeding in Animals Prescribed Platelet Aggregation Inhibitor

WELLESLEY, MA – November 18, 2014 -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5 Surgical Hemostat Device™, announced that an independent third party has obtained positive data from a preclinical study assessing the use of AC5™ in animals that had been treated with orally administered therapeutic doses of the blood thinner ticagrelor, which is currently marketed under the brand name Brilinta®. The results of the study are consistent with separate data obtained from two recently completed preclinical studies in which AC5 quickly stopped bleeding from surgical wounds created in rats following treatment with clinically relevant doses of the anticoagulant medication heparin; and another preclinical study which reported similar results with respect to the antiplatelet medications Plavix® (clopidogrel) and aspirin when used individually and in combination. Anticoagulant and antiplatelet medications are commonly referred to as “blood thinners.”

The study group intends to submit the data for publication. The research was led by Rudolf Urbanics, MD, PhD, and Domokos Csukas, DVM at Semmelweis University Faculty of Medicine in Budapest, Hungary within the Department of Surgical Research and Techniques. The research was sponsored by Arch. Also part of the research team was Dr. Rutledge Ellis-Behnke, Director of the Nanomedicine Translational Think Tank in the Department of Ophthalmology at the Medical Faculty Mannheim of the University of Heidelberg in Germany. Dr. Ellis-Behnke is also affiliated with three U.S. academic institutions, and he is an advisor to and co-founder of Arch.

In the present study, performance of AC5 was assessed as the time to hemostasis (TTH), or time to cessation of bleeding, from surgical wounds created in the livers of rats. The average TTH of a group of rats that had been pre-treated with clinically relevant doses of ticagrelor was compared to the TTH of rats that were not pre-treated. The anticoagulation effect of doses of ticagrelor was confirmed by measurements of platelet function. Importantly, after

AC5 was applied to the bleeding liver wound, the TTH among the groups was comparable, regardless of whether they were pre-treated with the antiplatelet drug.

In comparison, animals not pre-treated with ticagrelor and in which a saline control was used to stop bleeding took more than nine times as long to achieve hemostasis. Furthermore, animals that were administered ticagrelor and in which a saline control was used in lieu of AC5 to stop bleeding took more than 20 times as long to achieve hemostasis versus those treated with AC5, highlighting that antiplatelet medications do increase the baseline time to hemostasis.

Russell J. Andrews, MD, a neurosurgeon in Silicon Valley and San Jose, CA, and an unpaid advisor to the NASA Ames Nanotechnology and Smart Systems groups since 1998, said, “There is a tremendous need for improved products to stop bleeding and seal leaks, regardless of whether a patient is taking blood thinners. In particular, some of the newer antiplatelet medications, while being potentially more efficacious, also may increase the risk of bleeding even further. Products that prove to be safe and efficacious in animals and humans on these antiplatelet medications and other anticoagulants should be in great demand in the clinical marketplace. As a neurosurgeon, I would find such a universal topical hemostatic agent extremely useful in both elective and emergency neurosurgical procedures, from vascular disorders such as cerebral aneurysms and intracerebral hemorrhages to brain tumors to complex spine procedures, as well as nervous system trauma. My colleagues in general surgery, orthopedic surgery and trauma surgery should also find such a product indispensable.”

Terrence W. Norchi, MD, President and CEO of Arch Therapeutics, said, “This study

provides further evidence that AC5 can stop bleeding in living animals treated with commonly used and prescribed blood thinners, including the relatively newer antiplatelet medication Brilinta®, which is widely prescribed for prevention of thrombotic events in patients with acute coronary syndrome or myocardial infarction. This additional research represents an exciting feature of AC5 that should differentiate it from many existing hemostatic solutions currently on the market. If AC5 is approved for commercialization, it could offer a potential solution to many of the patients on this medication who might be at risk for excessive bleeding during surgery.”

About Arch Therapeutics, Inc.

Arch Therapeutics, Inc. is a medical device company developing a novel approach to stop bleeding (hemostasis) and control leaking (sealant) during surgery and trauma care. Arch is developing products based on an innovative self-assembling peptide technology platform to make surgery and interventional care faster and safer for patients. Arch's flagship development stage product candidate, known as the AC5 Surgical Hemostatic Device ™, is being designed to achieve hemostasis in minimally invasive and open surgical procedures.

Notice Regarding Forward-Looking Statements

This news release contains "forward-looking statements" as that term is defined in Section 27(a) of the Securities Act of 1933, as amended, and Section 21(e) of the Securities Exchange Act of 1934, as amended. Statements in this press release that are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, references to novel technologies and methods, our business and product development plans and projections, or market information. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with developing new products or technologies and operating as a development stage company, our ability to retain important members of our management team and attract other qualified personnel, our ability to raise the additional funding we will need to continue to pursue our business and product development plans, our ability to develop and commercialize products based on our technology platform, and market conditions. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in the reports and other documents we file with the SEC, available at www.sec.gov.

On Behalf of the Board,

Terrence W. Norchi, MD

Arch Therapeutics, Inc.

Contact:

ARTH Investor Relations

Toll Free: +1-855-340-ARTH (2784) (US and Canada)

Email: investors@archtherapeutics.com

Website: www.archtherapeutics.com

Or

Richard Davis

Chief Financial Officer

Arch Therapeutics, Inc.

Phone: 617-431-2308

Email: rdavis@archtherapeutics.com

Website: www.archtherapeutics.com